TY - JOUR
T1 - International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn
AU - for the International Collaboration for Transfusion Medicine Guidelines (ICTMG)
AU - Lieberman, Lani
AU - Lopriore, Enrico
AU - Baker, Jillian M.
AU - Bercovitz, Rachel S.
AU - Christensen, Robert D.
AU - Crighton, Gemma
AU - Delaney, Meghan
AU - Goel, Ruchika
AU - Hendrickson, Jeanne E.
AU - Keir, Amy
AU - Landry, Denise
AU - La Rocca, Ursula
AU - Lemyre, Brigitte
AU - Maier, Rolf F.
AU - Muniz-Diaz, Eduardo
AU - Nahirniak, Susan
AU - New, Helen V.
AU - Pavenski, Katerina
AU - dos Santos, Maria Cristina Pessoa
AU - Ramsey, Glenn
AU - Shehata, Nadine
N1 - Publisher Copyright:
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
PY - 2022/7
Y1 - 2022/7
N2 - Haemolytic disease of the newborn (HDN) can be associated with significant morbidity. Prompt treatment with intensive phototherapy (PT) and exchange transfusions (ETs) can dramatically improve outcomes. ET is invasive and associated with risks. Intravenous immunoglobulin (IVIG) may be an alternative therapy to prevent use of ET. An international panel of experts was convened to develop evidence-based recommendations regarding the effectiveness and safety of IVIG to reduce the need for ETs, improve neurocognitive outcomes, reduce bilirubin level, reduce the frequency of red blood cell (RBC) transfusions and severity of anaemia, and/or reduce duration of hospitalization for neonates with Rh or ABO-mediated HDN. We used a systematic approach to search and review the literature and then develop recommendations from published data. These recommendations conclude that IVIG should not be routinely used to treat Rh or ABO antibody-mediated HDN. In situations where hyperbilirubinaemia is severe (and ET is imminent), or when ET is not readily available, the role of IVIG is unclear. High-quality studies are urgently needed to assess the optimal use of IVIG in patients with HDN.
AB - Haemolytic disease of the newborn (HDN) can be associated with significant morbidity. Prompt treatment with intensive phototherapy (PT) and exchange transfusions (ETs) can dramatically improve outcomes. ET is invasive and associated with risks. Intravenous immunoglobulin (IVIG) may be an alternative therapy to prevent use of ET. An international panel of experts was convened to develop evidence-based recommendations regarding the effectiveness and safety of IVIG to reduce the need for ETs, improve neurocognitive outcomes, reduce bilirubin level, reduce the frequency of red blood cell (RBC) transfusions and severity of anaemia, and/or reduce duration of hospitalization for neonates with Rh or ABO-mediated HDN. We used a systematic approach to search and review the literature and then develop recommendations from published data. These recommendations conclude that IVIG should not be routinely used to treat Rh or ABO antibody-mediated HDN. In situations where hyperbilirubinaemia is severe (and ET is imminent), or when ET is not readily available, the role of IVIG is unclear. High-quality studies are urgently needed to assess the optimal use of IVIG in patients with HDN.
KW - alloimmunization
KW - evidence-based guidelines
KW - haemolytic disease of the newborn
KW - intravenous immunoglobulin
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85128283134&partnerID=8YFLogxK
U2 - 10.1111/bjh.18170
DO - 10.1111/bjh.18170
M3 - Article
C2 - 35415922
AN - SCOPUS:85128283134
SN - 0007-1048
VL - 198
SP - 183
EP - 195
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -